Is Daivobet good for psoriasis?

Daivobet® ointment is used only on skin affected by plaque-type psoriasis. Psoriasis is a skin disorder in which skin cells are overactive. The calcipotriol in Daivobet® ointment treats the overactive skin cells. The betamethasone dipropionate relieves redness, swelling, itching and irritation of the skin.

How effective is Dovobet?

Results. The Dovobet gel strategy allows a 5% reduction in the number of patients who could potentially be treated with more expensive therapies (biologics and conventional systemic drugs) in comparison with the Dovobet ointment strategy, with a consequent impact on costs for the National Healthcare Service.

What is Daivobet cream used for?

Daivobet is used to treat adults with psoriasis (a disease causing red, scaly patches on the skin). It is available as a gel and ointment and is used topically (applied on the skin). Daivobet contains two active substances: calcipotriol and betamethasone.

How long does it take for Dovobet gel to work?

Most patients see obvious results after 2 weeks, even if the psoriasis is not yet cleared at that point. Contact your doctor if you have used more than 15 grams in one day. Excessive use of Dovobet may also cause a problem with calcium in your blood, which usually normalises when discontinuing treatment.

Is Daivobet available in Europe?

Daivobet is also available in the EU under the trade name Dovobet. The company that markets these medicines is Leo Pharmaceutical Products. Why was Daivobet reviewed?

What does the European Medicines Agency Review mean for Daivobet?

The European Medicines Agency has completed a review of Daivobet. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Daivobet in the European Union (EU). What is Daivobet?

Why was Daivobet referred to the CHMP?

On 10 March 2010, Leo Pharmaceutical Products referred Daivobet to the CHMP in order to harmonise the marketing authorisations for the product in the EU. What are the conclusions of the CHMP?